Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer - Syndax Pharmaceuticals ( NASDAQ:SNDX )

2 days ago

On Tuesday, Syndax Pharmaceuticals Inc SNDX revealed topline results from the relapsed or refractory ( R/R ) mutant NPM1 ( mNPM1 ) acute myeloid leukemia ( AML ) cohort in the pivotal Phase 2 portion of the AUGMENT-101 trial of revumenib.

Ticker	Sentiment	Impact
SNDX	Somewhat Bullish	32 %